Sign in

    Hannah Adeoye

    Research Analyst at JPMorgan Chase & Co.

    Hannah Adeoye's questions to Surrozen, Inc./DE (SRZN) leadership

    Hannah Adeoye's questions to Surrozen, Inc./DE (SRZN) leadership • Q4 2022

    Question

    Hannah Adeoye from JPMorgan Chase & Co. asked about the half-life of SZN-1326 and the expected dosing regimen or frequency for a future multiple ascending dose study. She sought to understand what data provides comfort that the previously observed adverse events won't recur over longer dosing intervals.

    Answer

    CEO Craig Parker stated that the half-life of SZN-1326 is approximately 5 days based on primate studies. He explained that the biological effects could be longer-lasting than the PK half-life suggests, potentially allowing for an every-other-week or even less frequent dosing regimen. Parker noted that the final dosing frequency for the Phase Ib study has not yet been determined and will depend on further human PK data.

    Ask Fintool Equity Research AI

    Hannah Adeoye's questions to Surrozen, Inc./DE (SRZN) leadership • Q4 2022

    Question

    Hannah Adeoye from JPMorgan Chase & Co. asked about the half-life of SZN-1326 and the expected dosing regimen or frequency for a future multiple ascending dose study. She also sought to understand what data provides comfort that the previously observed adverse events will not occur over longer dosing intervals.

    Answer

    CEO Craig Parker stated that the half-life of SZN-1326 is approximately 5 days in primates. He noted that the biological effects could be longer-lasting than the pharmacokinetic half-life suggests, potentially allowing for an every-other-week or even less frequent dosing regimen. However, he clarified that the dosing plan for the Phase Ib study has not yet been finalized and will depend on the full human PK data from different dose levels.

    Ask Fintool Equity Research AI